Identification of Pyroptosis-Related Gene Signatures and Construction of the Risk Model to Predict BCR in Prostate Cancer

Overview

Journal Front Mol Biosci

Specialty Biology

Date 2022 Jul 11

PMID 35813821

Authors

Miaomiao Wang

Haoran Xia

Qiuxia Yan

Wen Liu

Ming Liu

Xuan Wang

Affiliations

Soon will be listed here.

Abstract

Prostate cancer is one of the most common malignant tumors in men. Pyroptosis is related to tumor immune infiltration and tumor microenvironment (TME) and has been confirmed to be related to the progression of a variety of tumors. However, the relationship between prostate cancer and pyroptosis, as well as TME and tumor immune infiltration, has not been discussed yet. We obtained and combined the RNA-seq data of prostate cancer from TCGA and GEO databases, analyzed the differential expression of pyroptosis-related genes (PRGs), and divided them into two groups according to the PRG expression level. The relationship between pyroptosis subtypes and the TME of prostate cancer was further verified, and the differential expression genes (DEGs) in the two subtypes were identified. The relationship between the DEGs and clinicopathology was explored and KEGG and GO enrichment analysis was conducted; it was found that most DEGs were enriched in immune-related pathways. Then, we randomly divided datasets into training and testing sets, performed the LASSO and multicox progression analysis, selected eight genes as prognostic signatures and used the eight genes, calculated the risk score, and then separated the entire cohort into high- and low-risk groups. The prognosis between two groups and the 1-, 3-, and 5-year ROC curves of biochemical relapse (BCR) were verified in training, testing, and the entire cohort, respectively. The TME, CSC index, mutation, and drug susceptibility were also discussed.

Citing Articles

Identification of anoikis-related gene signatures and construction of the prognosis model in prostate cancer.

Kang W, Ye C, Yang Y, Lou Y, Zhao M, Wang Z Front Pharmacol. 2024; 15:1383304.

PMID: 38957390 PMC: 11217483. DOI: 10.3389/fphar.2024.1383304.

Disulfidptosis-related genes serve as potential prognostic biomarkers and indicate tumor microenvironment characteristics and immunotherapy response in prostate cancer.

Zhou R, Lu D, Mi J, Wang C, Lu W, Wang Z Sci Rep. 2024; 14(1):14107.

PMID: 38898043 PMC: 11187134. DOI: 10.1038/s41598-024-61679-y.

Prognosis and diagnosis of prostate cancer based on hypergraph regularization sparse least partial squares regression algorithm.

Huang R, Ge Z, Xu G, Zeng Q, Jiang B, Xiao G Aging (Albany NY). 2024; 16(11):9599-9624.

PMID: 38829766 PMC: 11210239. DOI: 10.18632/aging.205889.

A review focusing on the role of pyroptosis in prostate cancer.

Liu Z, Kuang S, Chen Q Medicine (Baltimore). 2023; 102(50):e36605.

PMID: 38115248 PMC: 10727670. DOI: 10.1097/MD.0000000000036605.

Identification and validation of obesity related genes signature based on microenvironment phenotypes in prostate adenocarcinoma.

Liang L, Shang J, Zhang Y, Xu Y, Zhouteng Y, Wen J Aging (Albany NY). 2023; 15(19):10168-10192.

PMID: 37788005 PMC: 10599753. DOI: 10.18632/aging.205065.

References

Hinshaw D, Shevde L . The Tumor Microenvironment Innately Modulates Cancer Progression. Cancer Res. 2019; 79(18):4557-4566. PMC: 6744958. DOI: 10.1158/0008-5472.CAN-18-3962. View

Cookson B, Brennan M . Pro-inflammatory programmed cell death. Trends Microbiol. 2001; 9(3):113-4. DOI: 10.1016/s0966-842x(00)01936-3. View

Bastian P, Ellinger J, Wellmann A, Wernert N, Heukamp L, Muller S . Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. Clin Cancer Res. 2005; 11(11):4097-106. DOI: 10.1158/1078-0432.CCR-04-1832. View

Liu Z, Guo C, Li J, Xu H, Lu T, Wang L . Somatic mutations in homologous recombination pathway predict favourable prognosis after immunotherapy across multiple cancer types. Clin Transl Med. 2021; 11(12):e619. PMC: 8684773. DOI: 10.1002/ctm2.619. View

Azzouni F, Godoy A, Li Y, Mohler J . The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases. Adv Urol. 2012; 2012:530121. PMC: 3253436. DOI: 10.1155/2012/530121. View

Visco Z, Sfakianos G, Grenier C, Boudreau M, Simpson S, Rodriguez I . Epigenetic Regulation of Claudin-1 in the Development of Ovarian Cancer Recurrence and Drug Resistance. Front Oncol. 2021; 11:620873. PMC: 8019902. DOI: 10.3389/fonc.2021.620873. View

Li Z, Li H, Zhang Y, Zhang X, Wang B, Liu J . Value of long non-coding RNA Rpph1 in esophageal cancer and its effect on cancer cell sensitivity to radiotherapy. World J Gastroenterol. 2020; 26(15):1775-1791. PMC: 7183868. DOI: 10.3748/wjg.v26.i15.1775. View

Zhang J, Gong A, Young C . ZNF185, an actin-cytoskeleton-associated growth inhibitory LIM protein in prostate cancer. Oncogene. 2006; 26(1):111-22. DOI: 10.1038/sj.onc.1209769. View

Fang Y, Tian S, Pan Y, Li W, Wang Q, Tang Y . Pyroptosis: A new frontier in cancer. Biomed Pharmacother. 2019; 121:109595. DOI: 10.1016/j.biopha.2019.109595. View

10.

Liu Z, Guo C, Dang Q, Wang L, Liu L, Weng S . Integrative analysis from multi-center studies identities a consensus machine learning-derived lncRNA signature for stage II/III colorectal cancer. EBioMedicine. 2021; 75:103750. PMC: 8686027. DOI: 10.1016/j.ebiom.2021.103750. View

11.

Xia X, Wang X, Cheng Z, Qin W, Lei L, Jiang J . The role of pyroptosis in cancer: pro-cancer or pro-"host"?. Cell Death Dis. 2019; 10(9):650. PMC: 6733901. DOI: 10.1038/s41419-019-1883-8. View

12.

Xiao Q, Wang L, Supekar S, Shen T, Liu H, Ye F . Structure of human steroid 5α-reductase 2 with the anti-androgen drug finasteride. Nat Commun. 2020; 11(1):5430. PMC: 7591894. DOI: 10.1038/s41467-020-19249-z. View

13.

Wang Y, Gao W, Shi X, Ding J, Liu W, He H . Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. Nature. 2017; 547(7661):99-103. DOI: 10.1038/nature22393. View

14.

Liang Z, Liu H, Wang F, Xiong L, Zhou C, Hu T . LncRNA RPPH1 promotes colorectal cancer metastasis by interacting with TUBB3 and by promoting exosomes-mediated macrophage M2 polarization. Cell Death Dis. 2019; 10(11):829. PMC: 6828701. DOI: 10.1038/s41419-019-2077-0. View

15.

Nakai Y, Nonomura N . Inflammation and prostate carcinogenesis. Int J Urol. 2012; 20(2):150-60. DOI: 10.1111/j.1442-2042.2012.03101.x. View

16.

Van den Broeck T, van den Bergh R, Arfi N, Gross T, Moris L, Briers E . Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. Eur Urol. 2018; 75(6):967-987. DOI: 10.1016/j.eururo.2018.10.011. View

17.

Zhuang Z, Cai H, Lin H, Guan B, Wu Y, Zhang Y . Development and Validation of a Robust Pyroptosis-Related Signature for Predicting Prognosis and Immune Status in Patients with Colon Cancer. J Oncol. 2021; 2021:5818512. PMC: 8616665. DOI: 10.1155/2021/5818512. View

18.

Jorgensen I, Rayamajhi M, Miao E . Programmed cell death as a defence against infection. Nat Rev Immunol. 2017; 17(3):151-164. PMC: 5328506. DOI: 10.1038/nri.2016.147. View

19.

Kovacs S, Miao E . Gasdermins: Effectors of Pyroptosis. Trends Cell Biol. 2017; 27(9):673-684. PMC: 5565696. DOI: 10.1016/j.tcb.2017.05.005. View

20.

Zhang Y, Tang L . Inhibition of breast cancer cell proliferation and tumorigenesis by long non-coding RNA down-regulation of miR-122 expression. Cancer Cell Int. 2017; 17:109. PMC: 5698957. DOI: 10.1186/s12935-017-0480-0. View